Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

Drugs and weight loss often go hand in hand, but the journey can feel overwhelming—especially when your wallet takes a hit.

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

The company's financial results should remain strong for a while. Analysts expect earnings per share (EPS) to grow at an ...

Here's what to know about weight loss drugs such as Wegovy and Zepbound. CR helps you decide whether semaglutide or ...

Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...

Cheesecake Factory gains after report activist pushing for breakup. Lilly sues companies selling compounded Zepbound, ...

The costs for a similar control group of patients not taking ... The researchers didn't track long-term use of Lilly's newer ...

Prime Therapeutics reviewed pharmacy and medical claims data for 3,046 people with commercial health plans that cover GLP-1 ...